scholarly journals Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Richard Beasley ◽  
James Harper ◽  
Grace Bird ◽  
Harriette Dunphy ◽  
Alex Semprini ◽  
...  
Keyword(s):  
Dose Response ◽  
Beta Agonist ◽  
Fixed Dose ◽  
Severe Exacerbation ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Fast Onset ◽  
The One ◽  
Long Acting ◽  
Relationship Of

Abstract Background and objective The dose-response relationship of inhaled corticosteroid (ICS)/fast-onset long acting beta agonist (LABA) reliever therapy has not been formally addressed. The objective of this retrospective analysis is to ascertain from the available evidence whether ICS/fast-onset LABA administered as reliever therapy has a different dose-response relationship than maintenance fixed dose ICS/fast-onset LABA therapy in reducing risk of severe exacerbations. Methods A systematic literature review was undertaken to identify randomised controlled trials (RCTs) in which randomised treatments included either i) budesonide/formoterol reliever monotherapy versus budesonide/formoterol fixed dose maintenance with short acting beta agonist (SABA) reliever therapy, or ii) budesonide/formoterol reliever therapy in addition to budesonide/formoterol maintenance versus higher fixed dose maintenance budesonide/formoterol with SABA as reliever therapy. Eligible studies were reviewed to allow determination of the relative potency and efficacy of the comparator regimens to reduce the risk of a severe exacerbation. Results The one RCT of budesonide/formoterol reliever monotherapy showed a 4.6-fold (95% CI 2.9 to 7.3) greater potency than budesonide/formoterol fixed dose maintenance plus SABA reliever therapy in reducing the risk of severe exacerbations. In the one RCT that compared budesonide/formoterol maintenance and reliever therapy with higher fixed dose maintenance budesonide/formoterol plus SABA reliever therapy, there was an additional 26% (95% CI 4 to 42%) reduction in severe exacerbation risk with the addition of budesonide/formoterol reliever therapy to maintenance budesonide/formoterol, despite a 25% lower total budesonide/formoterol dose. Conclusion The limited available evidence suggests that budesonide/formoterol reliever therapy has greater potency and efficacy than budesonide/formoterol fixed dose maintenance plus SABA reliever therapy in reducing the risk of a severe exacerbation. This is an important concept which has the potential to guide clinical practice in asthma, although the small number of studies available highlights the need for further research to better define these pharmacological properties.

Underestimation of Dose - Response Relationship with Particular Reference to the Relationship between the Dietary Intake of Mercury and its Concentration in Blood

1988 ◽  
Vol 7 (2) ◽  
pp. 129-132 ◽  
Author(s):  
J.C. Sherlock ◽  
M.J. Quinn
Keyword(s):  
Linear Regression ◽  
Dietary Intake ◽  
Dose Response ◽  
Mercury Concentration ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Blood Mercury ◽  
Relationship Of ◽  
The Relationship ◽  
Blood Mercury Concentration

Wide discrepancies have been observed between controlled and uncontrolled intake studies of the relationship of blood mercury concentration to intake of mercury. The probable reason for the apparent discrepancies is that the within-subject variation of mercury intake in the uncontrolled studies was almost certainly considerably larger than the within-subject variation in blood mercury concentration; in these circumstances, the apparent slope obtained from a linear regression of blood mercury on intake will invariably be much smaller than the true slope. Studies of the exposure or intake of any substance should therefore include a consideration of the likely within-subject variation in the exposure or intake relative to that in the effect.

A model analysis for dose–response relationship of warfarin in Japanese children: An introduction of the SIZE parameter

2016 ◽  
Vol 31 (3) ◽  
pp. 234-241 ◽  
Author(s):  
Saki Nakamura ◽  
Nao Watanabe ◽  
Naoki Yoshimura ◽  
Sayaka Ozawa ◽  
Keiichi Hirono ◽  
...  
Keyword(s):  
Dose Response ◽  
Model Analysis ◽  
Response Relationship ◽  
Size Parameter ◽  
Dose Response Relationship ◽  
Japanese Children ◽  
Relationship Of

The Dose-Response Relationship of Ondansetron in the Prophylaxis of Pediatric Postoperative Emesis

1994 ◽  
Vol 81 (SUPPLEMENT) ◽  
pp. A1351
Author(s):  
M. F. Watcha ◽  
P. J. Bras ◽  
J. Pennant ◽  
G. Cieslak ◽  
D. Burnette
Keyword(s):  
Dose Response ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Relationship Of

scholarly journals Investigations on the dose–response relationship of combined exposure to low doses of three anti-androgens in Wistar rats

2017 ◽  
Vol 91 (12) ◽  
pp. 3961-3989 ◽  
Author(s):  
Steffen Schneider ◽  
Karma C. Fussell ◽  
Stephanie Melching-Kollmuss ◽  
Roland Buesen ◽  
Sibylle Gröters ◽  
...  
Keyword(s):  
Dose Response ◽  
Wistar Rats ◽  
Low Doses ◽  
Response Relationship ◽  
Combined Exposure ◽  
Dose Response Relationship ◽  
Relationship Of

scholarly journals Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents

2015 ◽  
Vol 123 (6) ◽  
pp. 1337-1349 ◽  
Author(s):  
Friederike Haerter ◽  
Jeroen Cedric Peter Simons ◽  
Urs Foerster ◽  
Ingrid Moreno Duarte ◽  
Daniel Diaz-Gil ◽  
...  
Keyword(s):  
Dose Response ◽  
Urine Analysis ◽  
Ex Vivo ◽  
Neuromuscular Blocking ◽  
Response Relationship ◽  
Binding Assays ◽  
Dose Response Relationship ◽  
Competition Binding ◽  
Relationship Of

Abstract Background The authors evaluated the comparative effectiveness of calabadion 2 to reverse non-depolarizing neuromuscular-blocking agents (NMBAs) by binding and inactivation. Methods The dose–response relationship of drugs to reverse vecuronium-, rocuronium-, and cisatracurium-induced neuromuscular block (NMB) was evaluated in vitro (competition binding assays and urine analysis), ex vivo (n = 34; phrenic nerve hemidiaphragm preparation), and in vivo (n = 108; quadriceps femoris muscle of the rat). Cumulative dose–response curves of calabadions, neostigmine, or sugammadex were created ex vivo at a steady-state deep NMB. In living rats, the authors studied the dose–response relationship of the test drugs to reverse deep block under physiologic conditions, and they measured the amount of calabadion 2 excreted in the urine. Results In vitro experiments showed that calabadion 2 binds rocuronium with 89 times the affinity of sugammadex (Ka = 3.4 × 109 M−1 and Ka = 3.8 × 107 M−1). The results of urine analysis (proton nuclear magnetic resonance), competition binding assays, and ex vivo study obtained in the absence of metabolic deactivation are in accordance with an 1:1 binding ratio of sugammadex and calabadion 2 toward rocuronium. In living rats, calabadion 2 dose-dependently and rapidly reversed all NMBAs tested. The molar potency of calabadion 2 to reverse vecuronium and rocuronium was higher compared with that of sugammadex. Calabadion 2 was eliminated renally and did not affect blood pressure or heart rate. Conclusions Calabadion 2 reverses NMB induced by benzylisoquinolines and steroidal NMBAs in rats more effectively, i.e., faster than sugammadex. Calabadion 2 is eliminated in the urine and well tolerated in rats.

scholarly journals Dose‐response relationship of human CD34+ cells in an athymic rat model of myocardial infarction

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Ben Brooks ◽  
Jeff McKee ◽  
Deborah Rice ◽  
Bernhard Baumgartner ◽  
Delara Motlagh ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Dose Response ◽  
Rat Model ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Human Cd34 ◽  
Cd34 Cells ◽  
Relationship Of
Sign in / Sign up

Export Citation Format

Share Document